NIIMBL 2022-2023 Annual Report


This Annual Report covers accomplishments and activities from March 1, 2022 to June 30, 2023.

Dear Colleagues, 

We are pleased to present our 2022-2023 Annual Report. Through projects, NIIMBL-led Programs, and talent initiatives, our community continues to seize opportunities to drive innovations that will enhance patient access to medicines, strengthen our economy, and boost national security.  

In 2022-2023, we invested $11M in new technology projects in areas such as  mRNA vaccines, cell processing, critical quality attribute measurement, and reliability. We also invested $2.5M in workforce development projects to increase awareness of our industry and foster alternative education pathways for careers in the biopharmaceutical industry.  

Our NIIMBL-led Programs have matured and gained considerable momentum over the past year. We outfitted our lab space at NIIMBL headquarters with new equipment, allowing our industry members to collaborate and test new processes. And the continued progress in our American Rescue Plan projects is poised to help our nation prevent, prepare for, and respond to future health threats.  

As part of our commitment to increasing diversity within our industry, we expanded our well-received NIIMBL eXperience program to three new locations across the country. This approach offered 3x more students the opportunity to explore a variety of career paths in biopharmaceutical manufacturing.   

While we celebrate the success of the past year, we are even more thrilled to look toward the future. The progress our institute has made in just six years is a testament to the dedication and enthusiasm of our members and community.  We thank you for your continued commitment and look forward to collaborating on more advances in the years to come. 

Sincerely, The NIIMBL Team 

Cover of the 2022-2023 NIIMBL annual report